Simplex Trading’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $6.76M | Buy |
456,000
+137,000
| +43% | +$980K | ﹤0.01% | 985 |
|
|
2026
Q2 | $1.33M | Sell |
319,000
-250,400
| -44% | -$951K | ﹤0.01% | 2470 |
|
|
2026
Q1 | $2M | Buy |
569,400
+231,400
| +68% | +$740K | ﹤0.01% | 1819 |
|
|
2025
Q4 | $923K | Buy |
338,000
+12,700
| +4% | +$29.4K | ﹤0.01% | 2706 |
|
|
2025
Q3 | $705K | Sell |
325,300
-92,700
| -22% | -$219K | ﹤0.01% | 3418 |
|
|
2025
Q2 | $718K | Sell |
418,000
-52,800
| -11% | -$131K | ﹤0.01% | 3137 |
|
|
2025
Q1 | $1.57M | Sell |
470,800
-196,300
| -29% | -$1.01M | ﹤0.01% | 2261 |
|
|
2024
Q4 | $4.94M | Buy |
667,100
+381,600
| +134% | +$3.54M | ﹤0.01% | 1487 |
|
|
2024
Q3 | $2.68M | Sell |
285,500
-57,800
| -17% | -$548K | ﹤0.01% | 2021 |
|
|
2024
Q2 | $2.75M | Sell |
343,300
-557,700
| -62% | -$5.98M | ﹤0.01% | 1924 |
|
|
2024
Q1 | $13.4M | Buy |
901,000
+272,800
| +43% | +$3.18M | 0.01% | 943 |
|
|
2023
Q4 | $5.11M | Buy |
628,200
+86,700
| +16% | +$454K | ﹤0.01% | 1528 |
|
|
2023
Q3 | $2.46M | Buy |
541,500
+442,800
| +449% | +$2.89M | ﹤0.01% | 1906 |
|
|
2023
Q2 | $694K | Buy |
98,700
+83,500
| +549% | +$598K | ﹤0.01% | 2973 |
|
|
2023
Q1 | $92K | Sell |
15,200
-163,500
| -91% | -$1.13M | ﹤0.01% | 5244 |
|
|
2022
Q4 | $1.14M | Buy |
178,700
+17,400
| +11% | +$136K | ﹤0.01% | 2338 |
|
|
2022
Q3 | $1.54M | Sell |
161,300
-62,400
| -28% | -$720K | ﹤0.01% | 2203 |
|
|
2022
Q2 | $2.47M | Buy |
223,700
+107,500
| +93% | +$1.41M | ﹤0.01% | 1669 |
|
|
2022
Q1 | $1.93M | Buy |
116,200
+67,400
| +138% | +$1.04M | ﹤0.01% | 2148 |
|
|
2021
Q4 | $931K | Sell |
48,800
-71,400
| -59% | -$1.57M | ﹤0.01% | 2960 |
|
|
2021
Q3 | $3.19M | Hold |
120,200
| – | – | ﹤0.01% | 1614 |
|
|
2021
Q2 | $3.13M | Buy |
+120,200
| New | +$3.12M | ﹤0.01% | 1627 |
|
|
2021
Q1 | – | Sell |
-219
| Closed | -$1.02M | – | 9356 |
|
|
2020
Q4 | $1.02M | Buy |
219
+4
| +2% | +$159 | ﹤0.01% | 2542 |
|
|
2020
Q3 | $707K | Sell |
215
-392
| -65% | -$12K | ﹤0.01% | 2619 |
|
|
2020
Q2 | $1.67M | Sell |
607
-327
| -35% | -$10.8K | ﹤0.01% | 1656 |
|
|
2020
Q1 | $2.8M | Buy |
934
+753
| +416% | +$20K | ﹤0.01% | 1032 |
|
|
2019
Q4 | $501K | Sell |
181
-543
| -75% | -$12.4K | ﹤0.01% | 2755 |
|
|
2019
Q3 | $1.32M | Buy |
724
+414
| +134% | +$9.16K | ﹤0.01% | 1683 |
|
|
2019
Q2 | $760K | Buy |
310
+73
| +31% | +$1.1K | ﹤0.01% | 2172 |
|
|
2019
Q1 | $225K | Sell |
237
-225
| -49% | -$2.18K | ﹤0.01% | 3476 |
|
|
2018
Q4 | $408K | Sell |
462
-89
| -16% | -$858 | ﹤0.01% | 2421 |
|
|
2018
Q3 | $619K | Buy |
551
+515
| +1,431% | +$7.31K | ﹤0.01% | 2404 |
|
|
2018
Q2 | $46K | Sell |
36
-113
| -76% | -$1.65K | ﹤0.01% | 5140 |
|
|
2018
Q1 | $8K | Sell |
149
-14
| -9% | -$212 | ﹤0.01% | 4222 |
|
|
2017
Q4 | $24K | Buy |
163
+76
| +87% | +$610 | ﹤0.01% | 3130 |
|
|
2017
Q3 | $6K | Buy |
+87
| New | +$551 | ﹤0.01% | 4239 |
|
|
2017
Q2 | – | Sell |
-9
| Closed | -$1K | – | 6420 |
|
|
2017
Q1 | $1K | Sell |
9
-180
| -95% | -$1.32K | ﹤0.01% | 5674 |
|
|
2016
Q4 | $11K | Buy |
189
+56
| +42% | +$385 | ﹤0.01% | 3652 |
|
|
2016
Q3 | $5K | Sell |
133
-159
| -54% | -$1.34K | ﹤0.01% | 4274 |
|
|
2016
Q2 | $13K | Buy |
+292
| New | +$1.83K | ﹤0.01% | 3328 |
|
|
2016
Q1 | – | Sell |
-332
| Closed | -$18K | – | 5889 |
|
|
2015
Q4 | $18K | Buy |
+332
| New | +$2.3K | ﹤0.01% | 2787 |
|
Other funds holding IOVA
Simplex Trading's IOVA Position: Q3 2026 in Review
Simplex Trading increased its Iovance Biotherapeutics (IOVA) stake by 138% in Q3 2026, buying an estimated $1.25M and bringing the position to 300,685 shares worth $4.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1271.
Simplex Trading first reported a position in IOVA in Q3 2015 and has held it in 35 quarters since. 162 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.
- Simplex Trading held 300,685 shares of Iovance Biotherapeutics worth $4.46M as of Q3 2026.
- Simplex Trading bought 174,578 Iovance Biotherapeutics shares in Q3 2026, an estimated $1.25M.
- Iovance Biotherapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q3 2026, its #1271 holding.
- Simplex Trading first reported a position in Iovance Biotherapeutics in Q3 2015 and has held it in 35 quarters since.
- 162 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.
Based on Simplex Trading's 13F filing for Q3 2026, filed 4 Nov 2026.